Safety Warning - BORTEZOMIB
On November 6, 2017, Fresenius Kabi USA, LLC received FDA approval for its product, BORTEZOMIB for Injection. BORTEZOMIB for injection is indicated for the treatment of patients with multiple myeloma and the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. As a committed partner in the fight against multiple myeloma and mantle cell lymphoma, Takeda Oncology welcomes the availability of a different formulation of bortezomib for patients who need access to additional options. For more information, please click here.